This is a preview of subscription content, log in via an institution to check access.
References
de Rooij, J. et al. Nature 396, 474–477 (1998).
McCormick, F. Nature 363, 15–16 (1993).
Farnsworth, C. L. et al. Nature 376, 524–527 (1995).
Mattingly, R. R. & Macara, I. G. Nature 382, 268–272 (1996).
Ebinu, J. O. et al. Science 280, 1082–1086 (1998).
Kitayama, H., Sugimoto, Y., Matsuzaki, T., Ikawa, Y. & Noda, M. Cell 56, 77–84 (1989).
Bos, J. L. EMBO J. 17, 6776–6782 (1998).
Zwartkruis, F. J., Wolthuis, R. M., Nabben, N. M., Franke, B. & Bos, J. L. EMBO J. 17, 5905–5912 (1998).
York, R. D. et al. Nature 392, 622–626 (1998).
Altschuler, D. L., Peterson, S. N., Ostrowski, M. C. & Lapetina, E. G. J. Biol. Chem. 270, 10373–10376 (1995).
Franke, B., Akkerman, J. W. & Bos, J. L. EMBO J. 16, 252–259 (1997).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Downward, J. New exchange, new target. Nature 396, 416–417 (1998). https://doi.org/10.1038/24743
Issue Date:
DOI: https://doi.org/10.1038/24743
- Springer Nature Limited
This article is cited by
-
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
Investigational New Drugs (2011)